Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | GAA | P10253 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24681745 | 0.88 | KDR (0.51) | AURKAKDM4EGAAMEN1MAPT | |
| SCHEMBL395135 | 0.86 | KDM4E (0.55) | AURKAKDM4EGAAMEN1MAPT | |
| SCHEMBL30804597 | 0.86 | KDM4E (0.55) | AURKAKDM4EGAAMEN1MAPT | |
| SCHEMBL30804592 | 0.86 | KDM4E (0.55) | AURKAKDM4EGAAMEN1MAPT | |
| SCHEMBL16481161 | 0.86 | KDM4E (0.49) | AURKAKDM4EGAAMEN1MAPT | |
| SCHEMBL16481316 | 0.84 | LMNA (0.62) | AURKAKDM4EGAAMEN1MAPT | |
| SCHEMBL4193666 | 0.84 | KDM4E (0.62) | AURKAKDM4EGAAMEN1MAPT | |
| SCHEMBL11478901 | 0.84 | LRRK2 (0.57) | AURKAKDM4EGAAMEN1MAPT | |
| SCHEMBL28420428 | 0.84 | CXCR2 (0.59) | AURKAKDM4EGAAMEN1MAPT | |
| SCHEMBL28216056 | 0.84 | GAA (0.55) | AURKAKDM4EGAAMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283768-A | Preparation method of aryl acridine compound | 西安凯翔生物医药科技有限公司 | 2023-06-23 | — | — | CN | claimed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2025224512-A1 | NOVEL COMPOUND AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE 13 (HSD17B13) INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 삼진제약주식회사 | 2025-10-30 | — | — | WO | disclosed |
| CN-119053587-A | 5- [7- (3, 4-Dihydro-1H-isoquinoline-2-carbonyl) -1,2,3,4 tetrahydroisoquinolin-6-yl ] -1H-pyrrole-3-carboxamide derivatives, pharmaceutical compositions containing same and use thereof as pro-apoptotic agents | 法国施维雅药厂 | 2024-11-29 | — | — | CN | disclosed |
| US-11839138-B2 | Organic electroluminescent element and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-116283768-A | Preparation method of aryl acridine compound | 西安凯翔生物医药科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116283768-A | Preparation method of aryl acridine compound | 西安凯翔生物医药科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| WO-2001038312-A1 | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6028081-A | TREATING PEPTIC ULCERS | SSP CO., LTD. (JP) | 2000-02-22 | — | — | US | disclosed |
| CN-1211569-A | Substituted quinolone derivatives and pharmaceuticals containing the same | SSP CO LTD (JP) | 1999-03-24 | — | — | CN | disclosed |
| EP-0900789-A2 | Substituted quinolone derivatives and pharmaceuticals containing the same | SSP Co., Ltd. (JP) | 1999-03-10 | — | — | EP | disclosed |
| EP-0544488-B1 | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1998-03-11 | — | — | EP | disclosed |
| CN-1035001-C | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1997-05-28 | — | — | CN | disclosed |
| CN-1088906-A | The phenyl phenol leukotriene antagonists that replaces | LILLY CO ELI (US) | 1994-07-06 | — | — | CN | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
| US-4341898-A | DEHYDROGENATION-ISOMERIZATION REACTION IN PRESENCE OF LEWIS ACID | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1982-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | AURKA 624/4885KDM4E 26/4885GAA 1708/4885 |
| US-11639333-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | AURKA 624/4885KDM4E 26/4885GAA 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.